Preliminary Program: SATURDAY MAY 20
8 a.m.-Noon
CME Courses 1-3
9 a.m.-4 p.m.
CME Courses 4-9
10 a.m.-5 p.m.
APA Member Center Opens
Publishers' Bookfair Opens
Registration/Course Enrollment Opens
12:30 p.m.-3:30 p.m.
Industry-Supported Symposia
IS1. New Augmentation Strategies in Depression for Better Outcomes
Supported by GlaxoSmithKline
Polypharmacy in Depression: How Often is it Used and Why? Joshua A. Israel, M.D.
“How To” Augmentation Strategies in Resistant Depression Charles DeBattista, M.D.
When Does Polypharmacy Lead to Higher Remission Rates? Jonathan E. Alpert, M.D.
Adding Psychotherapy: Pearls for Improved Outcomes Amy Farabaugh, Ph.D.
Pharmacological Antidotes for Antidepressant-Induced Side Effects Anita H. Clayton, M.D.
IS2. Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Impact of Misdiagnosis of Bipolar Disorder on Patient Outcomes Claudia F. Baldassano, M.D.
Brains and Genes: Implications for the Treatment of Bipolar Disorder Kiki D. Chang, M.D.
Evaluation of Clinical Trials in Bipolar Disease Gary S. Sachs, M.D.
Impact of Patient Satisfaction With Treatment on Treatment Outcomes Holly A. Swartz, M.D.
IS3. Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric Research Supported by Forest Laboratories, Inc.
Assessing Statistical and Clinical Significance in Medical Research David J. Kupfer, M.D.
All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care Helena C. Kraemer, Ph.D.
Determining Efficacy: Sound Clinical Trial Design and Interpretation Cornelius Katona, M.D.
Treating Depression in Children and Adolescents: What's a Clinician to Do? Jeff Q. Bostic, M.D.
How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly Eric J. Lenze, M.D.
IS4. Bridging Sleep Science and Public Policy Supported by Takeda Pharmaceuticals North America, Inc.
The Science of Sleep David N. Neubauer, M.D.
Adolescents and School Start Times: The Intersection of Research and Public Policy R. Robert Auger, M.D.
Shiftwork, Sleep, and Performance Gregory Belenky, M.D.
Medical Education and Resident Duty Hours Phyllis C. Zee, M.D.
Insomnia and Public Policy Daniel J. Buysse, M.D.
1 p.m.-5 p.m.
CME Courses 10-14
6 p.m.-9 p.m.
Industry-Supported Symposia
IS5. Mania in Special Populations Supported by Shire US, Inc.
Recent Developments in the Treatment of Mania Robert M.A. Hirschfeld, M.D.
Recognition and Management of Child and Adolescent Bipolar Disorder Karen D. Wagner, M.D.
Bipolar Disorders in Women: Clinical and Metabolic Correlates Natalie L. Rasgon, M.D.
Bipolar Disorder in the Older Patient Brent P. Forester, M.D.
Recognizing Bipolar Disorder in African Americans William B. Lawson, M.D.
IS6. Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Functional Genomics and the Therapeutic Effects of Antipsychotics Anil K. Malhotra, M.D.
Insights From Neuroimaging to Guide Drug Choice and Development Carol A. Tamminga, M.D.
The Science of Subjective Tolerability: “Wellness” as a Treament Outcome Meera Narasimhan, M.D.
Recovery and Remission: Definitions, Dilemmas, and the Emergent Role of Peer Support Peter F. Buckley, M.D.
IS7. Bipolar Disorder: Creating a Consensus From Science to Public Policy Supported by Solvay Wyeth Pharmaceuticals
Treatment Considerations for Mania in Young Children Barbara Geller, M.D.
Treatment of Bipolar Disorder in U.S. Jails and Prisons Joseph R. Calabrese, M.D.
The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder Ellen Frank, Ph.D.
A Rational Approach for the Longitudinal Pharmacologic Management of Patients With Bipolar Disorder: An Argument for Changing Public Policy Mark H. Rapaport, M.D.
Alternative Pharmacologic Approaches to the Care of Bipolar Patients Alexander H. Fan, M.D.
IS8. Treatment-Resistant Depression: New Data, New Approaches Supported by Cyberonics, Inc.
Definitions and Clinical Characteristics of Treatment-Resistant Depression David L. Dunner, M.D.
Treatment Resistance and Genes: The Biology Versus Pharmacology Enigma Francisco A. Moreno, M.D.
PET of Chronic Vagal Nerve Stimulation in Severe, Treatment-Resistant Depression Jose V. Pardo, M.D.
Augmentation Strategies for Patients With Difficult-to-Treat MDD Alicia R. Ruelaz, M.D.
Brain Stimulation Therapies for Treatment-Resistant Depression Linda L. Carpenter, M.D. ▪
Information & Authors
Information
Published In
History
Published online: 17 February 2006
Published in print: February 17, 2006
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).